Christopher J. Kane

Cedars-Sinai Medical Center — United States

Medicine · Health Sciences

75h-index25.7kcitations740works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Diagnosis and Treatment(402), Prostate Cancer Treatment and Research(374), Urologic and reproductive health conditions(72), Renal cell carcinoma treatment(66), Cancer, Lipids, and Metabolism(64)

Publications738 total

Quantifying the Impact of Biochemical Recurrence After Radical Prostatectomy on Overall Mortality by Years of Life Lost: Results from the SEARCH Database
European Urology Oncology·2025
Supplementary Table 1 from Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH Cohort
2025Open Access
Post-hoc Estimation of a Quantitative Restriction Spectrum Imaging Biomarker for Prostate Cancer Detection Using Conventional MRI
2025Open Access
Disparities associated with race and ethnicity in pain management: a scoping review
International Journal of Clinical Pharmacy·2025Open Access
Single-Arm Investigator-Initiated Clinical Trial to Improve Germline Testing in At-Risk Patients With Prostate Cancer (IMPRINT)
JCO Oncology Practice·2025
Christopher J. Kane, MD, FACS
Urology Practice·2025
Reply by Authors
The Journal of Urology·2025
Single Center Experience with Rituximab and Daratumumab as Rescue Therapy for Post-Transplant FSGS Recurrence, Short-Term Follow-Up
American Journal of Transplantation·2025
Risks of Progression After Early Androgen Deprivation Therapy for Biochemical Recurrence After Radical Prostatectomy
The Journal of Urology·2025
Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value
The Journal of Urology·2025· 4 cited
PD35-12 BLOCKADE OF Wnt5A/ROR1 SIGNALING ACTIVATED THE ANDROGEN RESPONSE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) PATIENT-DERIVED MODELS
The Journal of Urology·2025
Editorial Comment on “The Impact of American Board of Urology Certification on Postoperative Outcomes for Patients: Assessing National Trends”
Urology·2025
Reply: Difficulty With Board Certification in Urology Is Associated With Adverse Medical License Actions
Urology Practice·2025
WHAT CLINICAL FACTORS PREDICT OUTCOMES IN RECURRENT METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER? RESULTS FROM THE SEARCH DATABASE
Urologic Oncology Seminars and Original Investigations·2025
Difficulty With Board Certification in Urology Is Associated With Adverse Medical License Actions
Urology Practice·2025· 2 cited
A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with <i>BRCA1/2</i> gene alterations (NePtune).
Journal of Clinical Oncology·2025
Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate‐ and low‐risk prostate cancer
Cancer·2025· 2 cited
Robotic Pelvic Lymphadenectomy: Standard and Extended Techniques
2025
New Voices of Fatherhood in South Africa in the Fathers Matter TV and Online Film Series
2025
A single centre, retrospective audit of adherence to the IMPORT-LOW recommendations on clip placement to facilitate partial breast radiotherapy
Clinical Oncology·2024Open Access
page 1 of 37Next →

Frequent Co-authors

Christopher L. Amling(20), William J. Aronson(15), Martha K. Terris(15), Stephen J. Freedland(15), Joseph C. Presti(12), Matthew R. Cooperberg(11), Peter R. Carroll(11), Edward M. Schaeffer(6), Judd W. Moul(6), James A. Eastham(5), Eric M. Horwitz(5), John F. Ward(5), Mack Roach(4), J. Brantley Thrasher(4), James L. Mohler(3), Andrew J. Armstrong(3), Charles A. Enke(3), Thomas A. Farrington(3), Celestia S. Higano(3), Michael Kuettel(3)